Subscribe to our Newsletters !!
A team of scientists from the Singapore-MIT Allian
Purified water is housed in an intermediate storag
High blood pressure is one of the most important r
Kiran Mazumdar-Shaw, Executive Chairperson of Bioc
Mumbai, India, 14th September: Cipla Li
Following the success of the promotion and informa
Tabernanthe iboga (iboga) is an indigenous plant i
The current client is a developer of new small molecule treatments for a wide range of respiratory diseases including asthma and COPD. The company has chosen to run dissolution tests on a new substance using ISAB’s leading in vitro lung simulation tool DissolvIt®.
DissolvIt® has been increasingly recognized in the inhalation industry as a leading solution for generating “IVIVC” data – that is in vitro dissolution and absorption data early on in the drug development process that closely predicts later-stage in vivo data. Such data can significantly reduce risk and costs early on in drug development.
ISAB’s contract research organization Inhalation Research Services (IRS), has signed a new contract worth 1.39 million SEK (130K Euros) with a US respiratory pharmaceutical company. The new client has chosen ISAB’s unique in vitro lung simulation tool DissolvIt® for its project.
With a growing body of publications like “In Vitro to ex Vivo/In Vivo Correlation (IVIVC) of dissolution kinetics from inhaled particulate solutes using air/blood barrier models” (Journal of Aerosol Science 2021) there is increasing interest in DissolvIt’s advanced capabilities.
ISAB CEO Manoush Masarrat: “We are very pleased to be working with this new US client. This clearly demonstrates the client’s confidence in our world-class expertise, and the leading in vitro capabilities of DissolvIt®. We are delighted to carry out this research and look forward to this exciting collaboration.”